Trial Profile

A Phase 3, Multicenter Study of [18F]APN-1607 Positron Emission Tomography in Subjects With Alzheimer's Disease Compared to Healthy Subjects

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 22 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Florzolotau (Primary)
Indications Alzheimer's disease; Dementia
Focus Diagnostic use; Registrational
Sponsors APRINOIA Therapeutics

Most Recent Events

20 May 2024 According to an APRINOIA Therapeutics media release, In Dec 2023, enrollment of Phase 3 trial to evaluate the efficacy and safety of APN-1607 for the diagnosis of Alzheimer's disease was completed in China and on Dec 8, 2023.
20 May 2024 Status changed to active, no longer recruiting, according to an APRINOIA Therapeutics media release
13 Sep 2022 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com